Accelrys Announces Inaugural NanoBiology Initiative Meeting and First Initiative Member; Meeting Will Launch International Collaboration to Develop NanoBiology Modeling and Workflow Solutions

Accelrys, Inc. (NASDAQ:ACCL), a leading provider ofscientific software and workflow solutions, today announced itsNanoBiology Initiative's first member organization, Italy's Universityof Trieste. The Accelrys NanoBiology Initiative is an internationalcollaborative framework to develop the scientific solutions thataddress critical challenges in drug delivery, diagnostics andbioengineering through multi-scale modeling. A leader in thecomputational analysis of nanomaterials for cancer detection, theUniversity of Trieste will join Accelrys scientists, Initiativemembers, and technical advisors at the NanoBiology Initiative'sinaugural meeting being held on September 25th at the SheratonCommander in Cambridge, Massachusetts.

For event registration and additional information, please visit:http://www.accelrys.com/info/initiatives/nanobio/initiative_meetings/sept2006.html

"The Accelrys NanoBiology Initiative was expressly designed toengage the world's foremost scientists across academia, government andindustry to identify the immediate needs in effective next-generationnanomaterials design for medical applications and to develop themodeling, simulation and data management solutions that address thoseneeds," said Mark Emkjer, CEO and President of Accelrys. "Aninvaluable addition to the Initiative, the University of Trieste, isthe first of many member organizations that will guide the developmentof - and ultimately be among the earliest to benefit from - Accelrys'resulting portfolio of nanobiology solutions."

"The rapid convergence of nanotechnology and biotechnology hasgenerated a need for design tools that can incorporate sufficientlydetailed models of the nanoscale molecular phenomena with thelarger-scale interaction and performance integral to their inclusionin biomedical devices," said Sabrina Pricl, Professor in theUniversity of Trieste's Department of Chemical, Environmental and RawMaterials Engineering. "Currently, there is no unique softwareavailable that performs that multi-scale task, a critical need that Ilook forward to help solving through our participation in the AccelrysNanoBiology Initiative."

The NanoBiology Initiative's first meeting will explore howmulti-scale modeling will enable the design of material properties andother factors critical to biomedical research and development.Attendees will gain the opportunity to collaborate with their peers inguiding the Initiative, learn directly from Accelrys' team oftechnical experts, try Accelrys' newly developed software fornanotechnology and nanobiology firsthand, and hear about the latest innanomaterials computational design from biomedical luminariesincluding:

-- Institute Professor Robert Langer, Massachusetts Institute of Technology - delivering an overview of cutting-edge advances in drug delivery and tissue engineering, two particularly promising application areas for computational modeling and simulation.

-- Professor Mauro Ferrari, University of Texas Health Science Center - discussing the role of multi-scale modeling in effectively advancing nanotechnology for medicine.

-- Professor Sabrina Pricl, University of Trieste - presenting specific opportunities and critical success factors for taking nanomaterials from computation through real world biomedical application. Topics include: drug design and resistance prediction.

-- Dr. Selena Chan, Senior Staff Scientist and Manager of Applications Development at Intel, will discuss combining nanotechnology with biology and medicine.

-- Dr. Reinier Akkermans, Accelrys - covering challenges and emerging solutions for the multi-scale simulation of soft nanomaterials and nanostructures including membranes and polymeric nanoparticles.

-- Dr. Michael Doyle, Accelrys - introducing Accelrys' Pipeline Pilot environment and how its capabilities for data management and modeling make it a powerful tool for multi-scale modeling and data analysis in nanobiology.

About Accelrys

Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software forcomputation, modeling, simulation, and the management and mining ofscientific data used by biologists, chemists and materials scientists,including nanotechnology researchers, for product design, as well asdrug discovery and development. SciTegic, Inc., a wholly ownedsubsidiary of Accelrys, has pioneered a new technology platform called"data pipelining" to process research discovery data withunprecedented flexibility. Accelrys technology and services aredesigned to meet the needs of today's leading research organizations.The company is headquartered in San Diego, California. For moreinformation about Accelrys, visit its website athttp://www.accelrys.com/.

Forward-Looking Statements

This press release contains forward-looking statements forpurposes of the Private Securities Litigation Reform Act of 1995 (the"Act"). Such statements, including statements relating to theNanoBiology Initiative and products resulting therefrom, are subjectto risks and uncertainties including, but not limited to, the risksthat the initiative will not be successful and that it will not resultin the timely or successful development or commercialization ofsoftware, as well as risks relating to market acceptance or demandrelating to the initiative or software, and other risks anduncertainties described in documents Accelrys has filed with theSecurities and Exchange Commission, including its most recent reporton Form 10-K. All forward-looking statements in this document arequalified entirely by the cautionary statements included in thisdocument and such filings. These risks and uncertainties could causeactual results to differ materially from results expressed or impliedby forward-looking statements contained in this document. Theseforward-looking statements speak only as of the date of this document.Accelrys claims the protection of the safe harbor for forward-lookingstatements contained in the Act and, disclaims any intent orobligation to publicly update or revise any forward-looking statementscontained herein to reflect any change in its expectations with regardthereto or any change in events, conditions or circumstances on whichany such statement is based.